Abstract Library

#4232 Aurora kinase A inhibition as a promising therapeutic strategy in ARID1A-mutated neuroendocrine carcinomas: First results of an in vitro and in vivo study

Introduction: Neuroendocrine carcinomas of the gastrointestinal tract (GEP-NEC) are rare but extremely aggressive tumor diseases with a 5-year survival rate of approximately 25%. The inactivating ARID1A mutation can be detected in approximately 40% of cases of GEP-NEC. Previous studies have shown that Aurora kinase A inhibition leads to selective synthetic lethality of ARID1A-deficient colorectal tumor cells.

Conference:

Presenting Author:

Authors: Viol F, Amin T, Sipos B, Fründt T, Smolkova B,

Keywords: Neuroendocrine Carcinoma, Mutation based Therapy, ARID1A, Aurora Kinase A,

#3852 Novel insights to study the potential of the somatostatin system in NETs and NECs

Introduction: Neuroendocrine tumors (NETs) and carcinomas (NECs) are a heterogeneous group of cancers with increasing incidence worldwide. Surgery is the only curative choice, whereas an effective pharmacological approach for disseminated disease is still lacking. Somatostatin (SS) receptors (SSTs) provide a suitable pharmacological target to treat NETs with SS analogues (SSAs). However, a large proportion of NETs and, particularly most NECs, are unresponsive or resistant to SSAs. The underlying causes remain poorly understood and alternative strategies are needed. Recently, cortistatin (CST), a neuropeptide analogue of SS with comparable affinity to SSTs, emerged as an anti-inflammatory player, with potential antitumoral features.

Conference:

Presenting Author: Mangili F

Authors: Mangili F, Moreno Montilla M, García Vioque V, Blázquez-Encinas R, Mantovani G,

Keywords: PanNET, PanNEC, Somatostatin receptor (SST), cortistatin, Somatostatin,

#3497 Activity and safety of metformin (MET), Everolimus (EVE) and Octreotide (OCT) in patients (pts) with advanced, well-differentiated (WD) pancreatic neuroendocrine tumors (pNETs). The prospective phase II MetNET-1 trial (NCT02294006). Interim analysis

Introduction: Preclinical and clinical evidences support a role for metformin as an antineoplastic agent in WD pNETs.

Conference:

Presenting Author: Pusceddu S

Authors: Pusceddu S, Prinzi N, Corti F, Beninato T, Milione M,

Keywords: pancreatic NET, metformin, somatostatin analogues, everolimus,

#3354 Cancer associated fibroblasts induce proliferation and therapeutic resistance in neuroendocrine tumors through STAT3 activation

Introduction: Cancer-associated fibroblasts (CAF) have been identified as relevant contributors to cancer progression and drug resistance in many tumors. Although neuroendocrine tumors (NET) are often associated with a strong stromal reaction, no study has addressed whether CAF are involved in progression and therapeutic resistance in NET.

Conference:

Presenting Author:

Authors: Amin T, Viol F, Fahl M, Eggers C, Awwad F,

Keywords: neuroendocrine tumor, cancer associated fibroblasts, NT-3, cell lines,

#3252 Streptozotocin resistant pancreatic neuroendocrine tumor cell lines as a tool to understand chemotherapy resistance in pNET

Introduction: Streptozotocin based chemotherapy is standard of care in patients with advanced pancreatic neuroendocrine tumors (pNET). Although partial remission can initially be achieved in up to 40% of patients, primary non-responders and development of secondary progression under therapy is a major clinical challenge. So far, the mechanism leading to streptozotocin resistance have not been elucidated.

Conference: 18th Annual ENETS Concerence (2021)

Presenting Author: Schrader J

Authors: Viol F, Amin T, Fahl M, Izbicki J, Schrader J,

Keywords: streptozotocin, pNET, MGMT,